title: Development of myelodysplastic syndrome in a patient with chronic myelogenous leukemia treated with imatinib.
authors.affiliation: Department of Laboratory Oncology.
authors.forename: Nabhajit
authors.initials: N
authors.lastname: Mallik
authors.forename: Anita
authors.initials: A
authors.lastname: Chopra
authors.forename: Akash
authors.initials: A
authors.lastname: Jha
authors.forename: Ajay
authors.initials: A
authors.lastname: Gogia
authors.forename: Rajive
authors.initials: R
authors.lastname: Kumar
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D002869:Chromosome Aberrations / Q000187:drug effects; D002872:Chromosome Deletion; D002890:Chromosomes, Human, Pair 20 / Q000235:genetics; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects*; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009006:Monosomy; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000175:diagnosis* / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate